Kendall Square

LabCentral 2023 Impact Report Details a Decade of Innovation and Economic Development for Biotech and Life Sciences Startups in Massachusetts

Retrieved on: 
星期二, 五月 7, 2024
Education, Health, Heart, Mentorship, Partnership, Research, Initial public offering, Kendall Square, LabCentral, Pharmaceutical industry

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- LabCentral, the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, today unveiled its 2023 Impact Report which covers LabCentral's first ten years of operation (2013-2023). The report quantifies LabCentral's unprecedented role as a growth engine in the Massachusetts life sciences industry in its first decade, including resident companies' aggregated funding, patents, clinical trials and job creation. It also includes LabCentral's 2023 impact metrics, including science-based operations, expanded facilities and programming.

Key Points: 
  • The report quantifies LabCentral's unprecedented role as a growth engine in the Massachusetts life sciences industry in its first decade, including resident companies' aggregated funding, patents, clinical trials and job creation.
  • It also includes LabCentral's 2023 impact metrics, including science-based operations, expanded facilities and programming.
  • 6,339 jobs – The 278 companies LabCentral has supported have added 6,339 new life sciences and biotech jobs to the economy, including 447 new jobs in 2023.
  • LabCentral resident companies range from start-ups researching and testing new ideas to growth-stage companies working on process development and scale-up biomanufacturing.

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups

Retrieved on: 
星期四, 五月 2, 2024
Immunology, Golden Ticket, ONO, Patient, Neurology, MBC, Kendall Square, The Golden Ticket, LabCentral, Organization

CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.

Key Points: 
  • CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
  • The Golden Ticket awards provide two promising early-stage R&D companies lab space and mentorship, components that are vital to the success of promising life science businesses.
  • The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.

BXP Completes Sale of 45% Interest in Kendall Square Life Sciences Property

Retrieved on: 
星期一, 三月 25, 2024
REIT, Science, Other Science, Commercial Building & Real Estate, Construction & Property, Norges Bank, Sale, AstraZeneca, NBIM, Kendall Square

BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, today announced that it has completed the previously announced sale of a 45% interest in 290 Binney Street, a life sciences development located in Kendall Square in Cambridge, Massachusetts, to Norges Bank Investment Management.

Key Points: 
  • BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, today announced that it has completed the previously announced sale of a 45% interest in 290 Binney Street, a life sciences development located in Kendall Square in Cambridge, Massachusetts, to Norges Bank Investment Management.
  • 290 Binney Street is a 16-story, 570,000 square foot laboratory/life sciences property currently under construction and 100% pre-leased to AstraZeneca, with initial occupancy expected in April 2026.
  • The properties – 290 Binney Street and 300 Binney Street – total 810,000 square feet and are each 100% pre-leased.
  • BXP retains a 55% interest in the joint ventures and provides development, property management, and leasing services for the ventures.

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Retrieved on: 
星期二, 三月 19, 2024
Other Manufacturing, Other Science, Technology, Research, General Health, Engineering, Manufacturing, Pharmaceutical, Other Professional Services, Medical Devices, Health Technology, Finance, Genetics, Nanotechnology, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Health, Hardware, Science, Innovation Center station, Gene editing, Cell, BRIC, RNA, Pear VC, Conscience, Capital, Messenger, Hope, Genome, Doctor of Philosophy, Bayer, Antibody, Kendall Square, CRISPR, Drug development, Multimedia, Small RNA, Silicon, Fine chemical

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Key Points: 
  • Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
  • Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications.
  • The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
  • “We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC.

ADA Forsyth to Relocate to 100 Chestnut in Somerville in January 2025

Retrieved on: 
星期三, 三月 13, 2024
Health, Commercial Building & Real Estate, Dental, Construction & Property, Research, Science, Faculty, Organization, The Forsyth Institute, DDS, Patient, Public, City, History, Doctor of Philosophy, Life, Gensler, Kendall Square, Ecosystem, Creativity, MBTA, LEED, Research institute, Economic development, AFI, NRL, Development, Management

The ADA Forsyth Institute (AFI), a global leader in oral health research and innovation, announced today that it will relocate to Somerville, MA in January 2025.

Key Points: 
  • The ADA Forsyth Institute (AFI), a global leader in oral health research and innovation, announced today that it will relocate to Somerville, MA in January 2025.
  • In 2025, all research facilities for ADA Forsyth will be centrally housed in the new Somerville, MA location.
  • "We're thrilled to welcome ADA Forsyth Institute to 100 Chestnut in Somerville.
  • The City of Somerville and the Brickbottom district are very fortunate to have an organization of AFI’s caliber join the neighborhood.”

North River Leerink’s Successful 100 Chestnut Street Development Continues Somerville’s Growth as a Leading Life Science and Innovation Hub

Retrieved on: 
星期四, 二月 29, 2024
Commercial Building & Real Estate, Construction & Property, Science, Other Science, VHB, Restaurant, Doctor of Philosophy, Multimedia, Investment, City, Growth, Overalls, CBRE, Ultragenyx, Art, Kendall Square, NRL, Health, JLL, JC, Heart, Andrea Consigli, Form Energy, Life, Research, Environment, Interior design

At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.

Key Points: 
  • At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.
  • ft. Life Science building that is 90% leased, reflecting NRL's passion and focus on developing world-class buildings that enable innovation and support the creation of sustainable and vibrant communities.
  • Our goal is to contribute towards the development of a rich, vibrant and diverse district focused on fostering Art and enabling innovation in the Life Science/Biotech industry,” said Jeff Leerink, Managing Partner at NRL.
  • And most recently, ADA Forsyth, a leading institute dedicated to improving oral and overall health through innovative research and community outreach, has leased 76,000 sq.

LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket" at LabCentral 238

Retrieved on: 
星期二, 三月 5, 2024
Diamond, Regenerative medicine, Biotechnology, Research, LabCentral, Investment, Golden Ticket, Kendall Square, Patient, Heart, Science, Pharmaceutical industry

NORTHBROOK, Ill. and CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, and Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced the LabCentral 238 Diamond Ticket award. The Diamond Ticket is the largest lab space award of its kind in the industry and provides an innovative, growth-stage biotech company with a $500,000 credit for private lab space at LabCentral 238, one of the newest facilities in the LabCentral network in the heart of Kendall Square. Interested companies can review program details and apply online before the April 5, 2024 deadline.

Key Points: 
  • Astellas' support is a key part of its commitment to discovering and advancing innovative science.
  • "LabCentral 238 has expanded the options for growth-stage biotechs that need more space and specialized biomanufacturing equipment, enabling them to "grow" inside the LabCentral network of facilities and remain in Kendall Square," said Johannes Fruehauf, co-founder and president of LabCentral.
  • "From the beginning, Astellas has been much more than a founding sponsor; they have been a true partner.
  • A select number of entrepreneurs will be invited to present virtually to a joint selection committee made up of representatives from LabCentral and Astellas in April 2024.

Meliora Therapeutics Establishes Leadership Team with Key Promotion and New Addition

Retrieved on: 
星期一, 二月 12, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Physics, Meliora, AI, Biology, Drug discovery, Kendall Square, Medicine, Biomedicine, University, Patient, CSO, Machine learning, Cancer, Pharmaceutical industry

“These leadership updates mark the beginning of a new phase for Meliora.

Key Points: 
  • “These leadership updates mark the beginning of a new phase for Meliora.
  • We are also excited to welcome Anand, whose experience in cancer biology will be critical in advancing the company’s mission,” said David Li, co-founder and CEO of Meliora Therapeutics.
  • Dr. Claudio Chuaqui’s promotion to CSO comes as Meliora rapidly progresses multiple projects in its internal pipeline under his leadership and expertise.
  • Meliora Therapeutics is discovering and developing small molecule oncology therapies for high value cancer targets with its proprietary machine learning powered platform, AnchorOmics.

KBRA Assigns Preliminary Ratings to BX 2024-BIO

Retrieved on: 
星期一, 一月 22, 2024
Professional Services, Finance, Kendall Square, KBRA, Methodology, CMBS, Government of Pakistan, BX, KLTV, Boston, Gateway, Engineering, NCF

KBRA announces the assignment of preliminary ratings to four classes of BX 2024-BIO, a CMBS single-borrower securitization.

Key Points: 
  • KBRA announces the assignment of preliminary ratings to four classes of BX 2024-BIO, a CMBS single-borrower securitization.
  • The collateral for the transaction is a $1.2 billion floating rate, interest-only mortgage loan.
  • The loan has an initial two-year term with three, one-year extension options and requires monthly interest-only payments based on a SOFR cap of 4.00%.
  • The loan is secured by the borrower’s fee simple interest in the Kendall Square Portfolio (“Kendall Square”) and Gateway of Pacific Phase I (“GoP Phase I”) property.

Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from Insight to Therapeutics

Retrieved on: 
星期五, 一月 12, 2024
Bell Labs, Patient, Bain Capital, University, Research, Biology, North Dakota State University, Kendall Square, Health, Midas List, Broad Institute, Entrepreneurship, Biotechnology, Biomedical Research, CRISPR, Science, Data science, Harvard University, AI, Drug discovery, Partner (business rank), Disease, Safety, Acceleration, Hospital, Therapy, Robotics, Machine learning, Massachusetts General Hospital, Ageing, Gene editing, Physician, Pharmaceutical industry

By relying solely on private funding, Arena will be able to quickly translate insight into discovery, distinguishing it from traditional models.

Key Points: 
  • By relying solely on private funding, Arena will be able to quickly translate insight into discovery, distinguishing it from traditional models.
  • Arena will support development efforts with its drug discovery platforms through preclinical studies and beyond, when appropriate.
  • When Arena's human biology approach elucidates a disease mechanism, Arena will form a company to translate that insight to the clinic.
  • These emerging companies, which might recruit external scientists and leaders, will all be developed within the resource-rich ecosystem of Arena.